Zhang et al. [9] reported that ATBF1 mutations were a novel predictive biomarker for NSCLC patients receiving immune checkpoint inhibitor treatment; they were positively correlated with known immunotherapy response biomarkers, including immune-related gene expression and T-cell infiltration biomarkers. This evidence concerns the gene ZFHX3 and non-small cell lung carcinoma.